Foley & Lardner LLP represented New Enterprise Associates (NEA) as the lead investor in the $200 million Series C financing for Abcuro, a clinical-stage biotechnology company. NEA was joined by additional investors Foresite Capital, RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn Inc., and funds and accounts managed by BlackRock, Eurofarma Ventures, and Soleus Capital.